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LETTERS
The fi rst confi rmed case of chikun-
gunya fever on Rodrigues Island was 
reported in February, followed by 56 
cases in March, 393 in April, and >80 
in May (9).
The increase in CDRs reported for 
the Republic of Mauritius during the 
chikungunya epidemic is similar to the 
fi ndings reported for the neighboring 
island of Réunion (10). Excess deaths 
in Réunion and the Republic of Mauri-
tius coincided with the epidemic curve 
of the chikungunya fever outbreak, 
which suggested an association be-
tween these 2 factors. No other events 
that may have negatively affected the 
health of persons living in the Repub-
lic of Mauritius in 2006 were report-
ed. However, because information on 
cause of death is unavailable, studies 
are needed to confi rm that the chikun-
gunya fever outbreak contributed to 
increased CDRs in 2006.
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Increasing 
Resistance in 
Commensal 
Escherichia coli, 
Bolivia and Peru
To the Editor: The global in-
crease of antimicrobial-drug resis-
tance, including resistance to the new 
and most potent antimicrobial agents, 
is a major public health concern. In 
low-resource countries, where bacte-
rial infections are still among the ma-
jor causes of death, especially for chil-
dren, it is of particular concern (1).
ANTRES (Towards Controlling 
Antimicrobial Use and Resistance in 
Low-income Countries—An Interven-
tion Study in Latin America) is a re-
search project on antimicrobial-drug 
use and resistance in low-resource coun-
tries of Latin America (see www.unifi .
it/infdis/antres/default.htm). In 2002,
 the baseline ANTRES study showed a 
high rate of fecal carriage of Escherich-
ia coli with acquired resistance to sever-
al antimicrobial drugs, especially older 
drugs (e.g., ampicillin, trimethoprim-
sulfamethoxazole, tetracycline, strep-
tomycin, and chloramphenicol), in 
preschool children from 4 urban set-
tings in Bolivia and Peru (2). We report 
the results of a second cross-sectional 
study, conducted in 2005, that evalu-
ated the evolution of antimicrobial-
drug resistance in the studied areas.
We studied healthy children 6–72 
months of age from each of 4 urban ar-
eas:  2 in Bolivia (Camiri, Santa Cruz 
Department; Villa Montes, Tarija De-
partment) and 2 in Peru (Yurimaguas, 
Loreto Department; Moyobamba, San 
Martin Department). The study design, 
sampling and inclusion criteria, meth-
ods, and ethical issues were the same 
as those of the baseline study (2). The 
study was carried out over 4 months 
(September–December 2005), the 
same seasonal period as in the previ-
ous study. No signifi cant differences 
in sex ratios were found among chil-
dren enrolled from the different areas, 
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whereas minor differences were found 
for age. No statistical differences were 
found between the 2002 baseline study 
and the 2005 study results in terms of 
numbers of children (3,193 vs. 3,174) 
and sex ratios (0.94 vs. 0.95) (Table). 
Statistical analyses were performed by 
using Stata 9.0 (Stata Corp., College 
Station, TX, USA). Logistic regression 
models were used to compare the anti-
microbial-drug resistance rates in 2002 
and 2005, considering the combined in-
fl uences of age, sex, city, and country.
Data from the 2005 survey con-
fi rmed high resistance rates for am-
picillin, trimethoprim-sulfamethoxa-
zole, tetracycline, streptomycin, and 
chloramphenicol. The differences in 
resistance rates observed between 
2002 and 2005 for these drugs, al-
though sometimes statistically sig-
nifi cant, are probably of limited epi-
demiologic relevance due to the high 
rates of antimicrobial-drug resistance 
found in the E. coli population in both 
surveys. The most relevant fi nding of 
the 2005 survey was the remarkable 
increase since 2002 in the resistance 
rates to fl uoroquinolones and expand-
ed-spectrum cephalosporins (Table). 
Molecular analysis showed that the 
dramatic increase in rates of resistance 
to expanded spectrum cephalosporins 
was mostly the result of dissemination 
of CTX-M-type extended-spectrum β-
lactamase determinants (3). Concern-
ing the association between sex and 
resistance rates, the higher resistance 
rates observed for some agents and in 
some settings for boys in the baseline 
study were not confi rmed, except in 1 
case (kanamycin in Camiri, p = 0.04) 
(2). Analysis by age (not performed 
for amikacin due to low numbers of 
resistant isolates) confi rmed the oc-
currence of higher resistance rates for 
the youngest age group and an overall 
decreasing trend by age for all agents, 
except ciprofl oxacin and gentamicin. 
For these 2 agents, resistance rates 
increased, although not signifi cantly 
(p = 0.95 and p = 0.55, respectively) 
(2). Although we did not specifi cally 
address factors potentially involved 
in this phenomenon, we will address 
them in future investigations.
Increasing resistance to fl uoro-
quinolones and expanded-spectrum 
cephalosporins among E. coli clinical 
isolates has been observed in several 
parts of the world and complicates 
the management of infections (4,5). 
Recently, intestinal colonization with 
fl uoroquinolone-resistant or extend-
ed-spectrum β-lactamase–producing 
E. coli of nonhospitalized persons 
has been described as an emerging 
phenomenon (6–9). Although the ex-
act clinical implications of this phe-
nomenon are not clearly established, 
colonization by these resistant strains 
is a public health threat at the com-
munity and hospital levels (8,9). The 
reasons for the increased prevalence 
of fecal carriage of these resistant E. 
coli strains by children from the stud-
ied areas are not clear. Data collected 
about household use of antimicrobial 
drugs excluded previous use of fl uo-
roquinolones and expanded-spectrum 
cephalosporins (C. Kristiansson et al., 
unpub. data). The increased preva-
lence of resistant E. coli strains in 
preschool children most likely refl ects 
increased exposure within a contami-
nated household setting, in the food 
chain, or both (6,8,10).
Our fi ndings support the need to 
continue monitoring the evolution of 
resistance in commensal E. coli, to 
evaluate the effects of these important 
reservoirs of resistance genes distrib-
uted in the community, to investigate 
the epidemiologic relationship with 
clinical isolates, and to defi ne the role 
of the food supply. Investigation into 
whether carriage of resistant strains in 
adults correlates with data on antimi-
crobial-drug use in hospitals and in the 
community would also be of interest.
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Table. Antimicrobial drug–resistance rates of Escherichia coli as part of commensal 
flora in children, Bolivia and Peru, 2002 and 2005* 
Drug† 2002 2005 p value‡
AMP 95 96 <0.05
CRO 0.1 1.7 <0.001
TET 93 93 NS
SXT 94 94 NS
CHL 70 69 NS
STR 82 92 <0.001
KAN 28 29 <0.05
GEN 21 27 <0.001
AMK 0.4 0.1 NA
NAL 35 57 <0.001
CIP 18 33 <0.001
*Expanded Table available online at www.cdc.gov/EID/content/14/2/338-T.htm. Prevalence 
expressed as percentages. In 2002, n = 3,174, mean age 34.8 mo; in 2005, n = 3,193, mean age 
33.7 mo (mean age p<0.05). 
†AMP, ampicillin; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; CHL, 
chloramphenicol; STR, streptomycin;  KAN, kanamycin; GEN, gentamicin; AMK, amikacin; NAL, 
nalidixic acid; CIP, ciprofloxacin.  
‡Wald test applied to establish the statistical significance of parameters obtained from logistic 
regression analysis; NS, not significant; NA, not applicable (due to lack of variability of data). 
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Plasmid-mediated 
Quinolone 
Resistance in 
Salmonella enterica, 
United Kingdom
To the Editor: Fluoroquino-
lones are broad-spectrum antimicro-
bial drugs used to treat many clinical 
infections. Salmonellosis is treated 
with fl uoroquinolones only in elderly 
or immunocompromised patients, but 
these drugs are also used for treating 
patients with enteric fever, invasive 
disease, or long-term salmonellae 
carriage. High-level fl uoroquinolone 
resistance is uncommon, but reduced 
susceptibility is increasing.
Since 1998, plasmid-mediated 
quinolone resistance encoded by qnr 
genes A, B, and S that confer low-
level resistance to nalidixic acid and 
reduced susceptibility to ciprofl oxacin 
has been identifi ed in several entero-
bacterial species, including Salmo-
nella. Their clinical importance is in 
facilitating resistance to potentially le-
thal levels of quinolone. Additionally, 
qnr genes are often associated with 
strains that produce extended-spec-
trum β-lactamases.
We recently reported identifi ca-
tion of qnr genes in Salmonella in the 
United Kingdom (1). Most isolates 
were associated with the Far East. 
Two isolates of S. Virchow were part 
of an outbreak associated with im-
ported cooked chicken from Thailand. 
During October 2006–April 2007, we 
monitored qnr genes in nontyphoidal 
salmonellae isolated in the United 
Kingdom that expressed reduced 
susceptibility to ciprofl oxacin (MIC 
0.125–1.0 μg/mL) with concomitant 
susceptibility to nalidixic acid (MIC 
<16 μg/mL). This resistance pheno-
type is a useful marker for the qnr 
gene as the sole quinolone resistance 
determinant (1). 
Recent studies showed that iso-
lates of Salmonella spp. and Esch-
erichia coli with decreased suscep-
tibility to ciprofl oxacin (MICs >0.06 
μg/mL and 0.5 μg/mL, respectively), 
but with susceptibility or intermedi-
ate resistance to nalidixic acid (MIC 
8–16 μg/mL and 4–8 μg/mL, respec-
tively), all had qnrA or qnrS genes 
but lacked mutations in the topoi-
somerase genes (2,3). Strains with 
ciprofl oxacin MICs >1 μg/mL were 
also included to monitor involve-
ment of qnr genes in development of 
high-level ciprofl oxacin resistance. 
Breakpoint concentrations used are 
based on long-term studies within the 
Health Protection Agency Laboratory 
of Enteric Pathogens. Ciprofl oxacin 
Etest (AB Biodisk, Solna, Sweden) 
results were interpreted according to 
manufacturer’s procedures. A total 
of 45 Salmonella spp. strains were 
tested. Screening for qnr genes by 
multiplex PCR identifi ed 37 isolates 
with qnrS and 2 carrying qnrB vari-
ants (Table) (4). However, the qnrB 
primer pair in this multiplex did not 
fully match all qnrB gene variants. 
PCR and sequencing using primers 
FQ1 and FQ2 (5) and qnrS-F and 
qnrS-R (1), were used to identify spe-
cifi c qnrB and qnrS gene variants.
The qnrS1-positive salmonellae 
belong to serotypes Typhimurium 
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